University

Edison Partners welcomes Rutgers to $365m fund
Rutgers University was among a string of limited partners for the growth equity firm's ninth fund, which was oversubscribed from its $300m target.
Rgenix generates $40m series C
The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.
Chrysalix brings Delft to RoboValley for first close
The Delft-affiliated fund has reached its first close on its way to a $120m target, having secured capital from a range of limited partners.
Theodorus unveils $23m fund
Université libre de Bruxelles has added a fourth Theodorus fund to its arsenal with an initial close of $23m and a target of up to $33.5m.
Orchard to orchestrate $173m IPO
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
Editorial: For the good of investors
As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
Principia achieves $122m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
MIT’s Engine hits $205m close
The MIT-affiliated Engine Fund has achieved a final close of more than $205m, above its initial target of $150m.

Other News

Institut Curie curates Honing Biosciences
Institut Curie has supplied an undisclosed sum to its second immuno-oncology spinout, Honing Biosciences, which will focus on improved drug delivery mechanisms.
Asarina diagnoses listing
Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
NuNano magnifies investment
Bristol microscopy technology spinout NuNano has secured cash from the university’s Enterprise Fund for a second time.
Madorra registers for $6m round
Stanford-StartX Fund is among medical device developer Madorra’s backers, along with Fogarty Institute of Innovation and OneVentures Healthcare.
Exonate nurtures UBEF investment
The Parkwalk-managed University of Bristol Enterprise Fund has joined parent IP Group to become an investor in macular degeneration-focused spinout Exonate.
Immune-Onc books $33m series B
Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.

Editor's Picks

Editorial: For the good of investors
As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Opportunities and challenges abound at PraxisAuril conference
PraxisAuril's spring conference continues to go from strength to strength, with one in three delegates a first-time attendant.
Big deal: QuantumScape fuels up on VW cash
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
test reg

Login

Not yet subscribed?

See your subscription offers here